Gelman, Andrew and Geurts, Hilde M. 2017. The statistical crisis in science: how is it relevant to clinical neuropsychology?. The Clinical Neuropsychologist, Vol. 31, Issue. 6-7, p. 1000.
Frölich, Lutz Peters, Oliver Lewczuk, Piotr Gruber, Oliver Teipel, Stefan J. Gertz, Hermann J. Jahn, Holger Jessen, Frank Kurz, Alexander Luckhaus, Christian Hüll, Michael Pantel, Johannes Reischies, Friedel M. Schröder, Johannes Wagner, Michael Rienhoff, Otto Wolf, Stefanie Bauer, Chris Schuchhardt, Johannes Heuser, Isabella Rüther, Eckart Henn, Fritz Maier, Wolfgang Wiltfang, Jens and Kornhuber, Johannes 2017. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimer's Research & Therapy, Vol. 9, Issue. 1,
Herukka, Sanna-Kaisa Simonsen, Anja Hviid Andreasen, Niels Baldeiras, Ines Bjerke, Maria Blennow, Kaj Engelborghs, Sebastiaan Frisoni, Giovanni B. Gabryelewicz, Tomasz Galluzzi, Samantha Handels, Ron Kramberger, Milica G. Kulczyńska, Agnieszka Molinuevo, Jose Luis Mroczko, Barbara Nordberg, Agneta Oliveira, Catarina Resende Otto, Markus Rinne, Juha O. Rot, Uroš Saka, Esen Soininen, Hilkka Struyfs, Hanne Suardi, Silvia Visser, Pieter Jelle Winblad, Bengt Zetterberg, Henrik and Waldemar, Gunhild 2017. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia, Vol. 13, Issue. 3, p. 285.
El Haj, Mohamad and Antoine, Pascal 2017. Context Memory in Alzheimer’s Disease: The “Who, Where, and When”. Archives of Clinical Neuropsychology, p. 1.
de Wit, Paul F. M. and Derix, Mayke M. A. 2017. Neuropsychologisch onderzoek bij de ziekte van Alzheimer: een casusbeschrijving. Neuropraxis, Vol. 21, Issue. 2, p. 34.
Li, Kan Chan, Wenyaw Doody, Rachelle S. Quinn, Joseph Luo, Sheng and Leoutsakos, Jeannie-Marie 2017. Prediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data. Journal of Alzheimer's Disease, Vol. 58, Issue. 2, p. 361.
Gurevich, Pavel Stuke, Hannes Kastrup, Andreas Stuke, Heiner and Hildebrandt, Helmut 2017. Neuropsychological Testing and Machine Learning Distinguish Alzheimer’s Disease from Other Causes for Cognitive Impairment. Frontiers in Aging Neuroscience, Vol. 9,
Persson, Karin Barca, Maria Lage Eldholm, Rannveig Sakshaug Cavallin, Lena Šaltytė Benth, Jūratė Selbæk, Geir Brækhus, Anne Saltvedt, Ingvild and Engedal, Knut 2017. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, Vol. 44, Issue. 1-2, p. 12.
Kikkert, Lisette H.J. Vuillerme, Nicolas van Campen, Jos P. Hortobágyi, Tibor and Lamoth, Claudine J. 2016. Walking ability to predict future cognitive decline in old adults: A scoping review. Ageing Research Reviews, Vol. 27, p. 1.
Mazzeo, Salvatore Santangelo, Roberto Bernasconi, Maria Paola Cecchetti, Giordano Fiorino, Agnese Pinto, Patrizia Passerini, Gabriella Falautano, Monica Comi, Giancarlo Magnani, Giuseppe and Albani, Diego 2016. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. Journal of Alzheimer's Disease, Vol. 54, Issue. 4, p. 1495.
Spaan, Pauline E.J. and Duregger, Cornelia 2016. Episodic and semantic memory impairments in (very) early Alzheimer���s disease: The diagnostic accuracy of paired-associate learning formats. Cogent Psychology, Vol. 3, Issue. 1,
Galozzi, Sara Marcus, Katrin and Barkovits, Katalin 2015. Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids. Expert Review of Proteomics, Vol. 12, Issue. 4, p. 343.
Reitz, Christiane and Mayeux, Richard 2014. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical Pharmacology, Vol. 88, Issue. 4, p. 640.
Kennedy, Richard E. Cutter, Gary R. and Schneider, Lon S. 2014. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimer's & Dementia, Vol. 10, Issue. 3, p. 349.
Hill, Derek L.G. Schwarz, Adam J. Isaac, Maria Pani, Luca Vamvakas, Spiros Hemmings, Robert Carrillo, Maria C. Yu, Peng Sun, Jia Beckett, Laurel Boccardi, Marina Brewer, James Brumfield, Martha Cantillon, Marc Cole, Patricia E. Fox, Nick Frisoni, Giovanni B. Jack, Clifford Kelleher, Thomas Luo, Feng Novak, Gerald Maguire, Paul Meibach, Richard Patterson, Patricia Bain, Lisa Sampaio, Cristina Raunig, David Soares, Holly Suhy, Joyce Wang, Huanli Wolz, Robin and Stephenson, Diane 2014. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's & Dementia, Vol. 10, Issue. 4, p. 421.
Ferreira, Daniel Perestelo-PÃ©rez, Lilisbeth Westman, Eric Wahlund, Lars-Olof SarrÃa, Antonio and Serrano-Aguilar, Pedro 2014. Meta-Review of CSF Core Biomarkers in Alzheimerâ€™s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, Vol. 6,
Gordon, Craig and Martin, Daniel J 2013. Mild cognitive impairment. Expert Review of Neurotherapeutics, Vol. 13, Issue. 11, p. 1247.
Teipel, Stefan J. 2013. Risk and resilience: A new perspective on Alzheimer's disease. Geriatric Mental Health Care, Vol. 1, Issue. 3, p. 47.
Gonzalez-Palau, F. Franco, M. Jimenez, F. Parra, E. Bernate, M. and Solis, A. 2013. Clinical Utility of the Hopkins Verbal Test-Revised for Detecting Alzheimer's Disease and Mild Cognitive Impairment in Spanish Population. Archives of Clinical Neuropsychology, Vol. 28, Issue. 3, p. 245.
Abnormal levels of biomarkers in cerebrospinal fluid (CSF) and atrophy of medial temporal lobe (MTL) structures on magnetic resonance imaging (MRI) are being used increasingly to diagnose early Alzheimer's disease (AD). We evaluated the claim that these biomarkers can detect preclinical AD before behavioural (i.e. memory) symptoms arise.
We included all relevant longitudinal studies of CSF and MRI biomarkers published between January 2003 and November 2008. Subjects were not demented at baseline but some declined to mild cognitive impairment (MCI) or to AD during follow-up. Measures of tau and beta-amyloid in CSF, MTL atrophy on MRI, and performance on delayed memory tasks were extracted from the papers or obtained from the investigators.
Twenty-one MRI studies and 14 CSF studies were retrieved. The effect sizes of total tau (t-tau), phosphorylated tau (p-tau) and amyloid beta 42 (aβ42) ranged from 0.91 to 1.11. The effect size of MTL atrophy was 0.75. Memory performance had an effect size of 1.06. MTL atrophy and memory impairment tended to increase when assessed closer to the moment of diagnosis, whereas effect sizes of CSF biomarkers tended to increase when assessed longer before the diagnosis.
Memory impairment is a more accurate predictor of early AD than atrophy of MTL on MRI, whereas CSF abnormalities and memory impairment are about equally predictive. Consequently, the CSF and MRI biomarkers are not very sensitive to preclinical AD. CSF markers remain promising, but studies with long follow-up periods in elderly subjects who are normal at baseline are needed to evaluate this promise.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 20th November 2017. This data will be updated every 24 hours.